- Home
- AGEN vs INAC Comparison
AGEN vs INAC Comparison
Compare AGEN & INAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- INAC
- Stock Information
- Founded
- AGEN 1994
- INAC 2024
- Country
- AGEN United States
- INAC United States
- Employees
- AGEN N/A
- INAC N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- INAC
- Sector
- AGEN Health Care
- INAC
- Exchange
- AGEN Nasdaq
- INAC Nasdaq
- Market Cap
- AGEN 142.8M
- INAC 143.2M
- IPO Year
- AGEN 2000
- INAC 2025
- Fundamental
- Price
- AGEN $4.55
- INAC $9.95
- Analyst Decision
- AGEN Buy
- INAC
- Analyst Count
- AGEN 2
- INAC 0
- Target Price
- AGEN $14.50
- INAC N/A
- AVG Volume (30 Days)
- AGEN 395.5K
- INAC 30.7K
- Earning Date
- AGEN 11-11-2025
- INAC 01-01-0001
- Dividend Yield
- AGEN N/A
- INAC N/A
- EPS Growth
- AGEN N/A
- INAC N/A
- EPS
- AGEN N/A
- INAC N/A
- Revenue
- AGEN $101,706,000.00
- INAC N/A
- Revenue This Year
- AGEN $60.49
- INAC N/A
- Revenue Next Year
- AGEN N/A
- INAC N/A
- P/E Ratio
- AGEN N/A
- INAC N/A
- Revenue Growth
- AGEN N/A
- INAC N/A
- 52 Week Low
- AGEN $1.38
- INAC $9.92
- 52 Week High
- AGEN $7.34
- INAC $9.99
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- INAC N/A
- Support Level
- AGEN $4.36
- INAC N/A
- Resistance Level
- AGEN $5.20
- INAC N/A
- Average True Range (ATR)
- AGEN 0.27
- INAC 0.00
- MACD
- AGEN 0.04
- INAC 0.00
- Stochastic Oscillator
- AGEN 40.91
- INAC 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About INAC Indigo Acquisition Corp. Ordinary Shares
Indigo Acquisition Corp is a blank check company.